The present invention discloses a capsule supplement that can boost the immune system and offer advanced protection. The food supplement is a food composition for oral administration as an anti-inflammatory and immune booster. The invention achieves the results by using its anti-inflammatory properties, fats, carbohydrates, protein, fruits, minerals and vitamins, antioxidant and is fortified with: vitamin C, vitamin D, zinc, and bromelain. It improves overall health and wellness. The said supplement increases the body defenses against viruses and other illnesses. Unlike therapeutic interventions, this supplement composes of ingredients that are in the food category, which is the primary source of nutrients for the human body. It helps the body maintains its healthy normal functions by using its natural source of sustenance.

The invention relates to methods for treating COVID-19 by targeting the inflammasome/caspase1/pyroptosis axis as a key inflammatory pathway. In particular, the invention relates to treating a patient infected with SARS-CoV-2 with an effective amount of one or more compounds that directly or indirectly inhibit one or more pathways of the inflammasome/caspase1/pyroptosis axis.

The invention relates to a fusion protein containing a selective cell death-inducing enzyme system for use in the therapy and/or treatment of cancer and tumors in humans and animals, a process, and its use.

The present invention relates to a pharmaceutical composition which contains activated charcoal, Carum carvi extract, papain and, optionally, α-galactosidase and β-galactosidase for the treatment of gastrointestinal disorders.

The present invention is directed to novel systems and methods for treating dermal inflammatory disorders, such as psoriasis.

Disclosed is a dissolvable, gel-forming film, and methods for its use, comprising a water-soluble cellulose ether, a hydrophilic rheological modifying agent, and an active proteolytic enzyme or other drug substance. The gel-forming film has a water content of less than 15% w/w and is capable of forming a hydrogel when contacted with water or other aqueous medium. The disclosed films achieve delivery of stable proteolytic enzymes to the desired site of action in a manner that provides uniform delivery of the enzymes.

Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of dipeptide repeat proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.

Synthetic alphavirus-derived replicon expression systems comprising nucleic acid sequences encoding at least one modified nonstructural protein, and synthetic nucleic acid sequences encoding at least one heterologous protein are described. Methods of producing at least one heterologous protein in a cell, or of inducing an immune response in a subject by administering and/or expressing the synthetic alphavirus-derived replicon expression systems are provided.

Provided herein are methods for managing host immune responses to improve therapeutic outcomes in adeno-associated virus (AAV)-mediated gene therapy. Such methods may include administering a recombinant adeno-associated vims (rAAV) to a subject following administration of a CD 19 inhibitor, e.g., an anti-CD 19 antibody. The methods described herein can facilitate improved transgene expression, help overcome pre-existing NAbs, and/or permit redosing with the same or substantially similar rAAV or transgene.

Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologically active fragment thereof. Such methods and compositions may be employed to reduce, prevent, degrade and/or eliminate amyloid formation in the lysosome and/or extracellularly.